• Policy
• PVA, financial resources to register new drugs, not penaltie
• by Lee, Jeong-Hwan Oct 17, 2022 10:52pm

• Policy
• “No considerations made to protect generics” at NA audit
• by Lee, Jeong-Hwan Oct 17, 2022 10:52pm

• Policy
• 780,000 doses of Comirnaty 2 will be national lot released
• by Lee, Hye-Kyung Oct 17, 2022 06:03am

• Policy
• Hemlibra's benefit speeds up to strengthen accessibility
• by Lee, Jeong-Hwan Oct 17, 2022 06:03am

• Policy
• Proposal for improvement of omission of PE data submission
• by Lee, Jeong-Hwan Oct 14, 2022 05:53am

• Policy
• CDDC blindly opposes applying RSA to Tabrecta and Rybrevant
• by Lee, Jeong-Hwan Oct 14, 2022 05:53am

• Policy
• National lot release for Moderna's bivalent COVID-19 vaccine
• by Lee, Hye-Kyung Oct 13, 2022 06:08am

• Policy
• The loss of health insurance is close to 200 billion won
• by Lee, Jeong-Hwan Oct 13, 2022 06:08am

• Policy
• 99 items were granted generic exclusivity, none reimbursed
• by Lee, Tak-Sun Oct 12, 2022 05:50am

• Policy
• Ponesimod's Domestic Item License
• by Lee, Hye-Kyung Oct 12, 2022 05:50am